2024
Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use
Weiss E, Davis M, Asch R, D'Souza D, Cool R, Esterlis I. Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use. The International Journal Of Neuropsychopharmacology 2024, 27: pyae044. PMID: 39320043, DOI: 10.1093/ijnp/pyae044.Peer-Reviewed Original ResearchTrauma-related psychopathologyCannabis useDepressive symptomsPositron emission tomographyCross-diagnostic sampleMetabotropic glutamate receptor 5Treatment development effortsAssociated with depressive symptomsGlutamate receptor 5CU groupSample of individualsAvailability in vivoFrontolimbic regionsGlutamatergic systemGlutamatergic neurotransmissionMGlu5PsychopathologyReceptor 5Intersection of traumaExploratory analysisCannabisEmission tomographySymptomsParticipantsVmPFC
2023
Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing
Martin A, Ranganathan M, D’Souza D. Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing. 2023, 156-166. DOI: 10.1017/9781108943246.017.Peer-Reviewed Original ResearchMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsHealth teamsImpact of exposureCognitive symptomsCannabis dependenceAdverse effectsCannabisSynthetic cannabinoidsIllnessPsychosisCannabinoidsElectrophysiological indicesNew research findingsAssociationComplex associationSymptomsPutative modelNeurodevelopmentSchizophreniaImpairmentThe Acute Effects of Cannabinoids in Patients with Psychotic Illness
Ganesh S, Henquet C, Sewell R, Kuepper R, Ranganathan M, D’Souza D. The Acute Effects of Cannabinoids in Patients with Psychotic Illness. 2023, 225-239. DOI: 10.1017/9781108943246.023.Peer-Reviewed Original ResearchMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsAcute effectsHealth teamsPsychotic illnessImpact of exposureCannabis dependenceAdverse effectsIllnessCannabisCannabinoidsSynthetic cannabinoidsPsychosisNew research findingsAssociationComplex associationPatientsNeurodevelopmentPutative modelSchizophrenia
2022
Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users
Johnson E, Colbert S, Jeffries P, Tillman R, Bigdeli T, Karcher N, Chan G, Kuperman S, Meyers J, Nurnberger J, Plawecki M, Degenhardt L, Martin N, Kamarajan C, Schuckit M, Murray R, Dick D, Edenberg H, D’Souza D, Di Forti M, Porjesz B, Nelson E, Agrawal A. Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. Schizophrenia Bulletin 2022, 49: 778-787. PMID: 36545904, PMCID: PMC10154717, DOI: 10.1093/schbul/sbac196.Peer-Reviewed Original ResearchConceptsCannabis useAlcohol use disorderCognitive difficultiesSchizophrenia polygenic risk scoresFirst cannabis useDaily cannabis useCannabis usersSocial withdrawalUnusual experiencesCannabis involvementPolygenic risk scoresExpected directionGenetic riskUse disordersIndependent replication sampleLike experiencesGenetic liabilityCannabisSchizophreniaPolygenic riskPolygenic liabilityReplication sampleExperienceAnalytic sampleDisordersConsensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
D’Souza D, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal Of Biological Psychiatry 2022, 23: 719-742. PMID: 35315315, DOI: 10.1080/15622975.2022.2038797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWFSBP Task ForceRisk of psychosisAge of exposureRates of psychosisRecurrent psychosisTask ForceEndocannabinoid systemPsychosis outcomesConsensus paperHigh riskPsychotic disordersPsychotic statesPsychosisPotency of cannabisCriteria of causalityCannabisCannabinoidsLines of evidenceCannabis lawsRiskExposureDisordersEvidenceConfoundersIllness
2018
Chapter 4 Psychotomimetic and Cognitive Effects of Δ9-Tetrahydrocannabinol in Laboratory Settings
Cahill J, Gupta S, Cortes-Briones J, Radhakrishnan R, Sherif M, D'Souza D. Chapter 4 Psychotomimetic and Cognitive Effects of Δ9-Tetrahydrocannabinol in Laboratory Settings. 2018, 75-128. DOI: 10.1016/b978-0-12-804791-0.00004-5.Peer-Reviewed Original ResearchHuman laboratory studiesCognitive effectsFunctional magnetic resonance imagingDeleterious cognitive effectsCannabis use disorderArray of outcomesPsychophysiological correlatesNeural noiseWider clinical implicationsEEG measuresRisk of psychosisΔ9-tetrahydrocannabinolUse disordersLaboratory settingPsychotic disordersMethodological strengthsClinical implicationsElectroencephalographyCannabisSchizophreniaSingle Photon Emission Computerized TomographyPhoton Emission Computerized TomographyHealthy humansPsychosisMagnetic resonance imaging
2014
Gone to Pot – A Review of the Association between Cannabis and Psychosis
Radhakrishnan R, Wilkinson ST, D’Souza D. Gone to Pot – A Review of the Association between Cannabis and Psychosis. Frontiers In Psychiatry 2014, 5: 54. PMID: 24904437, PMCID: PMC4033190, DOI: 10.3389/fpsyt.2014.00054.BooksPsychotic disordersFamily historyEmergence of psychosisPolymorphisms of COMTPublic health policySymptoms of schizophreniaTrigger relapsePsychosis outcomesHigh riskEpidemiological studiesAcute exposurePsychotomimetic symptomsPsychophysiological abnormalitiesPersistent effectsCognitive deficitsCannabis useHealth policyCannabinoidsSymptomsGenetic factorsCannabisChildhood traumaDisordersStandard criteriaWarrants serious considerationImpact of Cannabis Use on the Development of Psychotic Disorders
Wilkinson ST, Radhakrishnan R, D’Souza D. Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports 2014, 1: 115-128. PMID: 25767748, PMCID: PMC4352721, DOI: 10.1007/s40429-014-0018-7.BooksAcute psychosisPsychotic disordersCannabis useAcute intoxicationPersistent psychotic disordersLater psychotic disorderPersistence of psychosisPersistent psychosisHealthy volunteersCognitive symptomsCannabis intoxicationCannabinoid usePsychosisVulnerable populationsComponent causesCannabisIntoxicationGenetic vulnerabilityDose responseSynthetic cannabinoidsChildhood abuseDisordersCannabinoidsPotential riskMore researchChapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis
Radhakrishnan R, Addy P, Sewell R, Skosnik P, Ranganathan M, D’Souza D. Chapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis. 2014, 423-474. DOI: 10.1016/b978-0-12-418679-8.00014-9.Peer-Reviewed Original ResearchPsychotic disordersCannabis exposureComponent causesCannabinoid receptor functionDevelopment of schizophreniaHeavy cannabis exposurePublic health policyCannabinoid exposureTrigger relapsePsychophysiological deficitsCognitive symptomsReceptor functionSchizophreniaHealth policyCannabinoidsPsychosisCannabisLines of evidenceDisordersFurther studiesSymptomsBiological mechanismsExposureIndividual vulnerabilityCause
2012
The Effect of Chronic Cannabinoids on Broadband EEG Neural Oscillations in Humans
Skosnik PD, D'Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, O'Donnell BF. The Effect of Chronic Cannabinoids on Broadband EEG Neural Oscillations in Humans. Neuropsychopharmacology 2012, 37: 2184-2193. PMID: 22713908, PMCID: PMC3422484, DOI: 10.1038/npp.2012.65.Peer-Reviewed Original ResearchConceptsNeural oscillationsAuditory steady-state responseCannabis usersCannabis groupGamma rangeChronic cannabis usersCentral cannabinoid-1 receptorsCognitive processesTransient ERPsChronic cannabisChronic cannabinoidsHz powerEEG dataCurrent studyEffects of cannabinoidsCannabisPsychopharmacological effectsExogenous cannabinoidsNaïve controlsElectroencephalographySpectral powerTrial powerEarly ageX frequencyERPComorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment
Addy P, Radhakrishnan R, Cortes J, D’Souza D. Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment. FOCUS The Journal Of Lifelong Learning In Psychiatry 2012, 10: 140-153. DOI: 10.1176/appi.focus.10.2.140.Peer-Reviewed Original ResearchComorbid substance use disorderSubstance use disordersUse disordersSubstance abuseHigh rateTreatment of schizophreniaCo-occurring disordersCourse of schizophreniaCocaine use disorderSelf-medication hypothesisCombination pharmacotherapyComorbid alcoholService utilizationLow compliancePatientsSchizophreniaSubstance useDisordersTreatmentDSM definitionCliniciansEpidemiologyThorough assessmentCannabisLatest findings
2011
The acute effects of cannabinoids in patients with psychotic illness
Henquet C, Sewell A, Kuepper R, Ranganathan M, D’Souza D. The acute effects of cannabinoids in patients with psychotic illness. 2011, 198-209. DOI: 10.1017/cbo9780511706080.019.Peer-Reviewed Original ResearchMental health teamsImpact of cannabisEffects of cannabisPublic health specialistsCannabinoid systemAcute effectsHealth teamsPsychotic illnessHealth specialistsMental illnessMental healthEpidemiological factsCannabisIllnessAlcohol researchCannabis sativaNew research findingsPatientsSchizophreniaCannabinoidsPreface
Castle D, Murray R, D'Souza D. Preface. 2011, xi-xii. DOI: 10.1017/cbo9780511706080.001.Peer-Reviewed Original Research
2010
Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia
Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. Brazilian Journal Of Psychiatry 2010, 32: 515-530. PMID: 20512267, DOI: 10.1590/s1516-44462010000500005.Peer-Reviewed Original ResearchConceptsPsychotic disordersCannabis exposureComponent causesCannabinoid receptor functionCauses of schizophreniaHeavy cannabis exposurePublic health policyCannabinoid exposureTrigger relapsePsychophysiological deficitsCognitive symptomsReceptor functionSchizophreniaHealth policyCannabinoidsLines of evidenceDisordersFurther studiesCannabisSymptomsPsychosisBiological mechanismsExposureIndividual vulnerabilityCause
2009
Cannabinoids and psychosis
Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. International Review Of Psychiatry 2009, 21: 152-162. PMID: 19367509, DOI: 10.1080/09540260902782802.Peer-Reviewed Original ResearchConceptsGeneral populationPsychotic disordersTrigger relapseCannabis usersCognitive symptomsCross-sectional studyIndividual vulnerabilityCannabis useCannabinoid receptor functionLongitudinal studyCase seriesPsychotic illnessPsychotic symptomsCannabisHealthy individualsSchizophreniaPharmacological studiesReceptor functionAutobiographical accountsPsychosisEarly exposureSymptomsTwo-fold increaseConsiderable evidenceComponent causes
2008
Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis
D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology 2008, 33: 2505-2516. PMID: 18185500, PMCID: PMC3799954, DOI: 10.1038/sj.npp.1301643.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmnesiaAttentionBrainDose-Response Relationship, DrugDouble-Blind MethodDronabinolDrug Administration ScheduleDrug ToleranceFemaleHallucinationsHallucinogensHumansHydrocortisoneMaleMarijuana AbuseMiddle AgedPerceptual DisordersProlactinPsychoses, Substance-InducedTachycardiaYoung AdultConceptsAmnestic effectsPerceptual alterationsDelta-9-TetrahydrocannabinolCannabis useSubjective effectsFrequent usersCannabisEffects of cannabinoidsIllicit substancesPsychotomimetic effectsEuphoric effectsHealthy controlsHealthy individualsMemoryImpairingPsychosisDose-related effectsIndividualsCortisolPsychotomimeticsAttentionPeopleUsersPlacebo-controlled studyEffect
2005
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedArousalCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolEndocrine SystemFemaleHumansInjections, IntravenousMaleMental RecallMiddle AgedMotor ActivityNeuropsychological TestsPerceptionPsychiatric Status Rating ScalesPsychotic DisordersPsychotropic DrugsSchizophreniaVerbal LearningConceptsSchizophrenia patientsAntipsychotic-treated schizophrenia patientsDelta-9-tetrahydrocannabinol effectsLong-term adverse eventsCognitive deficitsPlacebo-controlled studyDelta-9-THCTransient exacerbationAdverse eventsReceptor dysfunctionEndocrine effectsHealthy subjectsStudy participationPsychotic disordersPlasma prolactinSchizophrenia symptomsPatientsSchizophreniaCognitive effectsPerceptual alterationsDeficitsCannabisSubjectsAkathisiaExacerbation
2004
Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia
D'souza D, Cho H, Perry E, Krystal J. Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia. 2004, 142-165. DOI: 10.1017/cbo9780511543630.012.Peer-Reviewed Original ResearchReceptor dysfunctionCannabinoid compoundsCannabis consumptionPathophysiology of psychosisPathophysiology of schizophreniaRecent pharmacological studiesPrincipal psychoactive constituentEffects of exposurePostmortem studiesNormal controlsPsychotic symptomsPsychotic disordersPharmacological studiesPsychosisPsychoactive constituentPathophysiologyΔ9-tetrahydrocannabinolSchizophreniaCannabisDysfunctionAssociationPossible mechanismPatientsSymptomsPharmacological